Christiansen Peer, Mele Marco, Bodilsen Anne, Rocco Nicola, Zachariae Robert
From the Department of Plastic and Breast Surgery, Aarhus University Hospital, Aarhus, Denmark.
Department of Breast Surgery, Herlev Gentofte Hospital, Copenhagen, Denmark.
Ann Surg Open. 2022 Oct 5;3(4):e205. doi: 10.1097/AS9.0000000000000205. eCollection 2022 Dec.
The early randomized controlled trials revealed no differences in survival between breast-conserving surgery (BCS) and mastectomy. However, breast cancer treatment has undergone changes, and the results of recent population-based registry studies suggest superior long-term survival after BCS. To explore the current evidence, a systematic review and meta-ana lysis of population-based observational studies from 2010 and onward was conducted.
A literature search was conducted in the PubMed, Embase, and Cochrane databases to identify relevant literature. Keywords included "mastectomy," "breast conserving surgery," and "survival." The identified studies were narratively reviewed and effect sizes (hazard ratios [HRs]) for overall (OS) and breast cancer-specific survival (BCSS) were combined with random-effects models.
A total of 30 reports were included in the review, and results from 25 studies were included in the meta-analyses. Compared with mastectomy, BCS was associated with better OS (HR = 1.34 [1.20-1.51]; N = 1,311,600) and BCSS (HR = 1.38 [1.29-1.47]; N = 494,267). Selected subgroups of patients, based on lymph node status, age (<50 years/≥50 years), and radiation therapy after mastectomy (±), all showed better overall survival after BCS. The number (range 4-12) and type of prognostic variables adjusted for in the survival analyses of the studies did not statistically significantly moderate the differences in survival between BCS and mastectomy.
The combined findings from large population-based studies indicate that BCS is associated with survival benefit compared with mastectomy, suggesting that BCS be the recommended treatment of early breast cancer (T1-2N0-1M0) if a radical lumpectomy can be performed.
早期随机对照试验显示,保乳手术(BCS)和乳房切除术在生存率上无差异。然而,乳腺癌治疗已发生变化,近期基于人群的登记研究结果表明,保乳手术后的长期生存率更高。为探究当前证据,对2010年及以后基于人群的观察性研究进行了系统评价和荟萃分析。
在PubMed、Embase和Cochrane数据库中进行文献检索,以识别相关文献。关键词包括“乳房切除术”“保乳手术”和“生存率”。对识别出的研究进行叙述性综述,并使用随机效应模型合并总生存期(OS)和乳腺癌特异性生存期(BCSS)的效应量(风险比[HRs])。
该综述共纳入30篇报告,荟萃分析纳入了25项研究的结果。与乳房切除术相比,保乳手术与更好的总生存期(HR = 1.34 [1.20 - 1.51];N = 1,311,600)和乳腺癌特异性生存期(HR = 1.38 [1.29 - 1.47];N = 494,267)相关。根据淋巴结状态、年龄(<50岁/≥50岁)和乳房切除术后放疗(±)选择的患者亚组,均显示保乳手术后的总生存期更好。研究生存分析中调整的预后变量数量(范围4 - 12)和类型,并未在统计学上显著缓和保乳手术和乳房切除术在生存率上的差异。
基于大量人群研究的综合结果表明,与乳房切除术相比,保乳手术具有生存获益,这表明如果可以进行根治性肿块切除术,保乳手术应作为早期乳腺癌(T1 - 2N0 - 1M0)的推荐治疗方法。